西立伐他汀和普伐他汀治疗原发性高胆固醇血症患者长期疗效和安全性比较

目的：比较西立伐他汀和普伐他汀治疗原发性高胆固醇血症的长期疗效和安全性。方法：共有４５０例随机给予西立伐他汀或普伐他汀,超始剂量分别为０．１ｍｇ或１０ｍｇ／ｄ,６周后剂量加倍,再过６周剂量再次加倍至０．４ｍｇ／ｄ,普伐他汀４０ｍｇ／ｄ。结果：０．１ｍｇ西立伐他汀和１０ｍｇ普伐他汀降低ＬＤＬ－Ｃ分别为２４．７％与２３．２％;降低ＬＤＬ－Ｃ分别为３５．０％与３２．０％,具有显著性差异（Ｐ＝０．０２０６     

西立伐他汀和攻他汀治疗高胆固醇血症患者疗效比较

目的：探讨西立伐他汀及普伐他汀对高胆固醇血症患者疗效及安全性。方法：150例高胆固醇血症患者随机分为两组：西立伐他汀组75例和普伐他汀组75例，治疗8周后观察血脂变化和安全性，并加以比较。结果：两种药物均可显著降低总胆固醇（TC），血甘油三酯（TG），低密度脂蛋白－胆固醇（LDL－C），并可升高高密度胆蛋白－胆固醇（HDL－C),而两药的不良反应无显著差异。结论：西立伐他汀具有显著的降脂作用，在调脂的同时并可抑制血小板活性，改善胰岛素抵抗。     

西立伐他汀治疗高胆固醇血症的疗效

目的：探讨西立伐他汀治疗原发性高胆固醇血症的有效性及安全性。方法：分为３个阶段,第一阶段（Ａ阶段）为５周的单盲进入阶段,第二阶段（Ｂ阶段）为期８周,将４７０例患者随机分为０．１ｍｇ组（１１９例）、０．２ｍｇ组（１１７例）、０．３ｍｇ（１１６例）和安慰剂组（１１８例）,均为ｑｄ,睡前服用。Ｂ阶段结束时,ＬＤＬ－Ｃ水平较试验前降低≥２０％者,继续Ｂ阶段治疗（西立伐他汀或安慰剂）１６周（Ｃ阶段）,以延长     

国产瑞舒伐他汀与辛伐他汀治疗高胆固醇血症疗效比较

目的比较国产瑞舒伐他汀5、10mg与辛伐他汀治疗原发性高胆固醇血症疗效。方法对入选患者进行4周筛选,将筛选合格的受试者随机分配为瑞舒伐他汀5mg,瑞舒伐他汀10mg,辛伐他汀20mg,3组均每日服药1次,治疗期共8周,观察调脂疗效和安全性。结果治疗8周末,瑞舒伐他汀5mg,瑞舒伐他汀10mg,辛伐他汀20mg3组TC、LDL-C降低差异有统计学意义（P〈0．01）,TG降低和HDL-C升高差异无统计学意义（P〉0．05）。瑞舒伐他汀5mg,瑞舒伐他汀10mg,辛伐他汀20mg 3组间TC、LDL-C降低差异均无统计学意我（P〈0．05）,TG降低、HDL-C升高差异均无统计学意义（P〉0．05）。安全性：3组不良反应发生率差异均有统计学意义（P〉0．05）。结论瑞舒伐他汀5mg组、瑞舒伐他汀10mg组均能明显降低TC、TG、LDL-C,升高HDL—C,调脂疗效确切。瑞舒伐他汀安全性好。瑞舒伐他汀5mg、10mg可用于治疗原发性高胆固醇血症患者。     

阿托伐他汀与氟伐他汀治疗高胆固醇血症的对比研究

目的　探讨阿托伐他汀 (立普妥 )与氟伐他汀 (来适可 )对高胆固醇血症病人疗效及安全性。方法　 10 0例高胆固醇血症随机分成阿托伐他汀组 5 0例和氟伐他汀组 5 0例 ,治疗 6周后观察比较。结果　阿托伐他汀及氟伐他汀均能明显降低TC、TG、LDL C水平 (P <0 0 1或P <0 0 5 ) ,阿托伐他汀降TC、TG、LDL C的作用强于氟伐他汀 (P <0 0 5 ) ,两药均能升高HDL C水平 (P <0 0 5 ) ,但两组比较未达到显著差异 (P >0 0 5 )。两药不良反应均比较小 ,耐受性好。结论　阿托伐他汀降TC、TG、LDL C的作用优于氟伐他汀 ,但升高HDL C水平相似 ,两药均有良好的安全性。     

瑞舒伐他汀治疗高胆固醇血症的临床疗效研究

目的：探讨瑞舒伐他汀治疗高胆固醇血症的临床疗效。方法选取南华大学附属医院2012年8月—2013年10月收治的79例高胆固醇血症患者,按照用药方案分为对照组42例和观察组37例。对照组采用阿托伐他汀治疗,观察组采用瑞舒伐他汀治疗,比较两组治疗前后血脂变化以及不良反应发生率。结果两组患者治疗后TG、TC、LDL-C与治疗前比较,差异有统计学意义（ P<0.05）;治疗后观察组TC、LDL-C低于对照组,差异有统计学意义（P<0.05）。观察组不良反应发生率低于对照组,差异有统计学意义（P<0.05）。结论瑞舒伐他汀可有效改善高胆固醇血症患者血脂水平,安全性较高。     

瑞舒伐他汀与阿托伐他汀治疗高胆固醇血症的临床对比观察

目的：对比瑞舒伐他汀和阿托伐他汀治疗老年高胆固醇血症患者的临床疗效。方法将76例高脂血症患者随机分为研究组和对照组各38例。对照组予阿托伐他汀,研究组予瑞舒伐他汀。于每晚入睡前服用,分别于受试后的4周和8周随访,抽空腹肘静脉血,测定2组TC、TG、LDL-C、HDL-C。结果治疗前2组TC、TG、HDL-C、LDL-C水平差异无统计学意义（P＞0．05）。治疗后第4、8周2组TC、TG、LDL-C水平低于治疗前,HDL-C水平高于治疗前,且研究组优于对照组,差异均有统计学意义（P＜0．05）。研究组LDL-C达标率为89．5％高于对照组的76．3％,差异均有统计学意义（ P＜0．05）。结论瑞舒伐他汀组、阿托伐他汀组均能明显降低TC、TG、LDL-C,升高HDL-C,调脂疗效确切。瑞舒伐他汀的临床疗效优于阿托伐他汀,剂量更小,价格相对低廉,安全性相当,值得临床推广使用。     

西立伐他汀和辛伐他汀治疗高脂血症的作用比较

目的观察西立伐他汀对高胆固醇血症患者的调脂作用,并与辛伐他汀比较.方法32例高胆固醇患者随机分为两组,服药前及服药后4周测定血脂.结果(1)服药后4周总胆固醇(TC)分别降低了28.9%和28.0%(P值均<0.01),低密度脂蛋白胆固醇(LDL-C)水平分别降低了31.5%和32.5%(P值均<0.01).(2)西立伐他汀明显降低血清甘油三酯(TG)水平22.0%(P<0.05).(3)服西立伐他汀和辛伐他汀4周后脂蛋白(α)[LP(α)]水平分别降低了35.3%(P<0.01)和27.8%(P<0.05).结论西立伐他汀能显著降低高胆固醇血症患者血清TC和LDL-C,其作用与辛伐他汀相等,西立伐他汀降低TG作用优于辛伐他汀.     

瑞舒伐他汀与阿托伐他汀治疗老年高胆固醇血症疗效和安全性分析

目的:对比分析瑞舒伐他汀与阿托伐他汀治疗老年高胆固醇血症疗效和安全性.方法:将100例老年高胆固醇血症患者随机均分为观察组和对照组,观察组采用瑞舒伐他汀治疗,对照组采用阿托伐他汀治疗,比较两组血脂指标及不良反应发生情况.结果:观察组TC、TG、LDL-C水平降低程度及HDL-C水平升高程度均要优于对照组,差异有统计学意义(P＜0.05);两组不良反应发生率差异无统计学意义(P＞0.05).结论:瑞舒伐他汀与阿托伐他汀的安全性相当,但瑞舒伐他汀的临床疗效要优于阿托伐他汀,可在临床上推广.     

辛伐他汀5mg与普伐他汀10mg治疗高胆固醇血症的比较

目的：探讨低剂量辛伐他汀治疗高胆固醇血症的临床疗效及耐受性。方法：低、中度原发性高胆固醇血症病人６２例，随机分为２组，Ａ组３１例（男性２６例，女性５例；年龄６４±ｓ１４ａ）采用辛伐他汀５ｍｇ，ｐｏ，ｑｄ。Ｂ组３１例（男性２５例，女性６例；年龄６１±１３ａ）采用普伐他汀１０ｍｇ，ｐｏ，ｑｄ。疗程均为４ｗｋ。结果：辛伐他汀组在降低ＴＣ，ＬＤＬ＿ｃｈ及提高ＨＤＬ＿ｃｈ的平均变化率上分别为１７％±９％，２５％±１２％（Ｐ＜０．０１）和１１％±１１％（Ｐ＞０．０５），与普伐他汀组疗效相当，组间比较，Ｐ值＞０．０５。２种药物治疗期间病人均无显著不良反应。结论：小剂量辛伐他汀疗效可与普伐他汀媲美，５ｍｇ／ｄ可作为治疗高胆固醇血症的起始剂量     

多廿烷醇与普伐他汀治疗高脂血症的疗效和安全性

目的评价多廿烷醇治疗高脂血症,特别是高胆固醇血症的疗效和安全性。方法多甘烷醇组(试验组,多廿烷醇10mg·d~(-1))和普伐他汀组(对照组,普伐他汀10 mg·d~(-1))各119例。进行随机、双盲、双模拟、阳性药物平行对照试验。观察2组降脂疗效和不良反应发生情况。结果经过12 wk治疗,多廿烷醇组总胆固醇(TC)、低密度脂蛋白胆固醇(LDL)、TC-高密度脂蛋白胆固醇(HDL-C)/ HDL-C、载脂蛋白B_(100)(Apo B_(100))、脂蛋白(Lpa)治疗前分别为(6.6±s0.7)、(4.0±0.6)、(0.10±0.03)、(3.3±0.5)mmol·L~(-1)、(260±184)mg·L~(-1),治疗后分别为(6.0±1.3)、(3.5±0.8)、(O.09±0.04)、(2.7±0.8)mmol·L~(-1)、(130±130)mg·L~(-1),治疗后各指标较治疗前均有非常显著差异(P<0.01)。普伐他汀组TC、LDL-C、TC-HDL-C/HDL-C、Apo B_(100)、Lpa治疗前分别为(6.7±0.8)、(4.1±0.7)、(0.10±0.03)、(3.4±0.5)mmol·L~(-1)、(279±240)mg·L~(-1),治疗后分别为(6.0±1.3)、(3.5±0.9)、(0.09±0.03)、(2.8±0.8)mmol·L~(-1)、(182±213)mg·L~(-1),治疗后各指标较治疗前均有非常显著差异(P<0.01)。但2组相比较,调脂作用相似,无显著差异(P>0.05)。不良反应方面,多廿烷醇组(9.2%)明显少于普伐他汀组(18.5%),2组有显著差异(P<0.05)。不良反应大多较轻微,不需停药能自行缓解。结论多廿烷醇10 mg·d~(-1)降脂效果与普伐他汀10 mg·d~(-1)的疗效相当,均能明显降低TC、LDL-C、TC-HDL-C/ HDL-C、Apo B_(100)、Lpa。多廿烷醇的安全性优于普伐他汀,不良反应轻微,耐受性好。     

辛伐他汀、普伐他汀治疗原发性高胆固醇血症的疗效比较

目的:观察辛伐他汀(Sim)、普伐他汀(Pra)治疗原发性高胆固醇血症的疗效及安全性.方法:采用随机分组、平行对照的方法.81例患有原发性高胆固醇血症病人.随机分成2组,Sim组39例.Pra组42例.结果:经过12wk治疗,Sim组TC、TG、LDL-C分别由(7.42±1.33).(2.23±1.16),(4.60±1.18)mmol/L下降到(5.69±1.17),(1.65±0.75),(3.07±0.94)mmol/L(P<0.01).HDL-C治疗前后分别为(1.30±0.28).(1.28±0.49)mmol/L下降了1.5%(P>0.05);Pra组TC、TG、LDL-C分别由(7.14±1.20),(2.32±1.30),(4.64±1.37)mmol/L下降到(5.76±1.13),(1.88±1.07),(3.28±1.30)mmol/L(P<0.01),HDL-C治疗前后分别为(1.27±0.24),(1.31±0.29)mmol/L(P>0.05);2组血脂改变程度、疗效及不良反应经统计学处理无差异(P>0.05).结论:Sim 5mg/d,Pra 10mg/d对原发性高胆固醇血症的病人可获得较好的疗效.且使用方便.     

瑞舒伐他汀治疗老年冠心病患者高胆固醇血症的疗效及安全性研究

目的 评价瑞舒伐他汀治疗老年冠心病患者高胆固醇血症的疗效及按入院次序安全性,并与辛伐他汀作对比.方法 采用单盲随机对照的研究方法将87例年龄大于60岁的冠心病高胆固醇血症患者按入院次序随机分为瑞舒伐他汀组(44例)和辛伐他汀组(43例).瑞舒伐他汀组给予瑞舒伐他汀10 mg,1次/d;辛伐他汀组给予辛伐他汀20 mg,1次/d,疗程8周,观察两药的疗效及安全性.结果 瑞舒伐他汀组经8周治疗,血浆LDL-C下降幅度(43.2%)明显大于辛伐他汀组(35.3%),差异有统计学意义(P<0.05),瑞舒伐他汀组LDL-C达标率(85.1%)明显高于辛伐他汀组(59.8%),差异有统计学意义(P<0.05);瑞舒伐他汀组HDL-C升高幅度(6.5%)也明显大于辛伐他汀组(1.6%),2组比较差异具有统计学意义(P<0.05);瑞舒伐他汀组TC、TG降低幅度(分别为32.2%,17.O%)略优于辛伐他汀组(30.8%,15.2%),2组比较差异无统计学意义(P>0.05).患者用药过程中无严重不良事件发生,主要不良反应为轻度腹胀、乏力,2组间不良反应发生率比较差异无统计学意义.结论 对老年冠心病高胆固醇血症人群,瑞舒伐他汀具有更强的降脂效果和良好的安全性.

Abstract：

Objective To evaluate the efficacy and safety of rosuvastatin in aged patients with coronary heart disease and hypercholesterolemia.Methods The selected patients were randomly divided into the rosuvastatin group(n=44,rosuvastatin 10 mg,qn)and simvastatin group(n=43,simvastatin 20 mg,qn)for 8 weeks.Results After treatment of 8 weeks,the decrease of plasma low-density lipoprotein cholesterol(LDL-C)in rosuvastatin group (43.2%) was significantly greater than that of simvastatin group(35.3%)(P<0.05).Compliance rate of LDL-C in rosuvastatin group(85.1% was higher than that in the simvastatin group (59.8%).The rate of HDL-C increase in rosuvastatin group(6.5%) was significantly greater than that in simvastatin group (1.6%)(P<0.05).he rate of TC,TG decreasing in msuvastatin group (respectively 32.2%,17.0%) was slishfly better than that in the simvastatin group (30.8%VS 15.2%),there was no significant difference between two groups(P>0.05).In this study the main adverse reactions were mild abdominal distension,fatigue.Conclusion For elderly people with coronary heart disease with hypercholestemlemia,rosuvastatin has a high lipid-lowering effect and good safety.     

Chronic treatment with pravastatin prevents early cardiovascular changes in spontaneously hypertensive rats

Background and purpose:

This study investigates the effect of pravastatin on blood pressure, cardiovascular remodelling and impaired endothelial function induced as early signs of cardiovascular disease in young spontaneously hypertensive rats (SHR).

Experimental approach:

Eight-week-old SHR were treated for 4 weeks with pravastatin (20 mg·kg⁻¹·day⁻¹). Systolic blood pressure was measured periodically during the study using the tail-cuff method. At the end of the study, the left ventricular weight /body weight ratio was used as an index of left ventricular hypertrophy (LVH). Vascular function, superoxide (O₂^−.) production and structure were studied in aortic rings. Lipid peroxidation was measured in plasma (thiobarbituric acid reactive substances assay).

Key results:

Systolic blood pressure was lower in treated SHR than in control SHR, at the end of the study (171 ± 1 vs. 159 ± 2 mmHg, P < 0.05), and LVH was significantly reduced by pravastatin (2.7 ± 0.02 vs. 2.5 ± 0.01 mg·g⁻¹, P < 0.05). Vascular responses to sodium nitroprusside and phenylephrine were similar in both groups; nevertheless, the relaxation response to acetylcholine was higher in the treated rats (45.6 ± 2.6 vs. 58.1 ± 3.2 %, P < 0.05). Vascular O₂^−. and plasma thiobarbituric acid reactive substances were reduced by pravastatin treatment, and urinary nitrites was elevated. Finally aortic wall became thinner after pravastatin treatment.

Conclusions and implications:

Chronic treatment with pravastatin attenuated the increase of systolic blood pressure in SHR, prevented early LVH and improved vascular structure and function. These effects were accompanied by decreased measures of oxidative stress and improvements in NO production.     

Cerivastatin Gender Effect: Sub-analyses of Results from a Multinational,Randomised, Double-blind Study

Summary

We previously reported the results of a multicentre, randomised, double-blind, parallelgroup study comparing the efficacy and safety of cerivastatin 0.4?mg/day and cerivastatin

0.2?mg/day in patients with primary hypercholesterolaemia. Exploratory analysis in this study suggested a gender difference in the 0.4 mg group: mean low-density lipoprotein cholesterol (LDL-C) decreased by 44.4 ± 8.9% in women, compared with a mean decrease of 37.0 ± 0.9% in men (p < 0.046). This paper reports the results of further sub-analyses from this study. Overall in the per-protocol (PP) population, 71.5% (n = 73) of women taking cerivastatin 0.4 mg had an LDL-C decrease of > 40%, compared with 38.0% (n = 76) of men taking the same dose. In the cerivastatin 0.2 mg PP population, 34% (n = 17) of women had an LDL-C decrease of > 40%, compared with 19% (n = 18) of men. Mean LDL-C/HDL-C ratio decreased by 43% from baseline to the end of the study in the cerivastatin 0.4 mg PP group: –41.3% in males vs. –48.3% in females. In the cerivastatin 0.2 mg group, the decrease in LDL-C/HDL-C ratio from baseline to endpoint did not markedly differ between genders: –37.0% for males vs. –37.3% for females. Categorial analysis of the LDL-C/HDL-C ratio found that 90% of PP patients taking cerivastatin 0.4 mg, and 84% of PP patients taking cerivastatin 0.2 mg, had a low CHD risk (defined as a LDL-C/HDL-C ratio ≤ 3) after 8 weeks of treatment. The 6thand 95th percentiles of the distribution of LDL-C reduction from baseline revealed that 90% of PP patients taking cerivastatin 0.4 mg had an LDL-C reduction of between 22% and 56%. The mean LDL-C reduction for this 90% subset of patients was 40.1%. The same analysis for PP patients taking cerivastatin

0.2 mg found that 90% had an LDL-C reduction of between 13% and 49%. The mean LDL-C reduction in this 90% subset of patients was 31.5%. Of the patients taking cerivastatin 0.4 mg and valid for treatment according to National Cholesterol Education Program (NCEP) criteria, 71% (149/211) achieved NCEP targets for LDL-C at Week 16.     

Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects

AIMS: Previous work has shown that rifampicin, a potent inducer of several cytochrome P450 (CYP) enzymes and transporters, decreased the plasma concentrations of simvastatin acid by more than 90%. This study was conducted to investigate the effect of rifampicin on the pharmacokinetics of pravastatin. METHODS: In a randomised, cross-over two-phase study with a washout of 4 weeks, 10 healthy volunteers received a 5-day pretreatment with rifampicin (600 mg daily) or placebo. On day 6, a single 40 mg dose of pravastatin was administered orally. Plasma concentrations of pravastatin were measured up to 12 h by a sensitive LC-MS-MS method. RESULTS: During the rifampicin phase, the mean total area under the plasma concentration-time curve of pravastatin [AUC(0-infinity )] was 69% (range 24-220%) of the corresponding value during the placebo phase (P < 0.05, 95% confidence interval for the difference -51.9 - -0.4 ng ml-1.h). In five of the 10 subjects the AUC(0-infinity ) of pravastatin during the rifampicin phase was 50% or less of that during the placebo phase. Rifampicin had no significant effect on the peak concentration, elimination half-life or renal clearance of pravastatin. CONCLUSIONS: Rifampicin caused a statistically significant decrease in the plasma concentration of pravastatin given as a single oral dose to healthy subjects. However, the effect of rifampicin varied greatly between subjects. The mean rifampicin-induced decrease in pravastatin concentration was considerably smaller than that observed previously for simvastatin.     

瑞舒伐他汀钙治疗高胆固醇血症的有效性与安全性研究

目的探讨瑞舒伐他汀钙治疗高胆固醇血症的有效性和安全性,为临床安全用药提供参考。方法选择海南医学院附属医院2011年12月至2012年12月高胆同醇血症患者,经4周筛选出符合入选条件的患者129例,按随机数字表法分为3组。A组43例患者给予瑞舒伐他汀钙5mg治疗,B组43例患者给予10mg瑞舒伐他汀钙治疗,对照组43例患者给予10mg阿托伐他汀钙治疗,12周后对3组患者血脂指标进行观察,同时记录3组患者的不良反应。结果A组、B组、对照组治疗12周后LDL—C分别较治疗前降低2．2、2．3、1．8mmol／L;TC分别较治疗前降低2．2、2．3、1．8mmol／L;A组与B组下降幅度均大于对照组,组问比较差异有统计学意义（P〈0．05）。3组HDL—C较治疗前有明显升高,TG较治疗前明显降低,但组间比较差异无统计学意义（P〉0．05）。A组与B组无明显不良反应,对照组出现不良反应2例,其中1例为AST、ALT水平升高,不良反应发生率为4．6％。组间比较差异有统计学意义（P〈0．05）。结论瑞舒伐他汀钙能有效降低高胆固醇血症患者LDL—C、TC,具有显著的疗效与较高的安全性。